F13B抗体;F13B Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 293T and NIH/3T3 cell lysates, Primary antibody: P05697(HOXD8 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

The F13B antibody targets the beta subunit of coagulation Factor XIII (FXIII), a key zymogen in hemostasis and wound healing. FXIII circulates as a heterotetramer (A2B2) in plasma, where the catalytic A subunits (synthesized in hematopoietic cells) are non-covalently bound to carrier B subunits (produced in hepatocytes). During clot formation, thrombin activates FXIII to FXIIIa, which cross-links fibrin strands to stabilize blood clots and enhance tissue repair.

F13B antibodies are primarily used in diagnostic and research settings to quantify or detect FXIII-B levels. Deficiencies in FXIII, though rare, can cause life-threatening bleeding disorders. Acquired FXIII deficiency may occur through autoimmune antibodies against either subunit, with anti-F13B antibodies being less common than anti-F13A. These autoantibodies are associated with conditions like lupus or lymphoproliferative disorders.

In clinical diagnostics, F13B-specific antibodies enable ELISA-based assays to distinguish subunit-specific deficiencies or monitor FXIII replacement therapy. Researchers also utilize them to study FXIII biology, including subunit interactions and regulatory mechanisms. Recent studies explore their role in non-hemostatic processes, such as angiogenesis and extracellular matrix remodeling. Commercial F13B antibodies are typically monoclonal, validated for applications like immunoblotting and immunohistochemistry.